We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 98.27%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$1.98B
$7.51M 0.06%
128,666
– –
CFRX
52
DELISTED
ContraFect Corporation
CFRX
$7.28M 0.06%
5,057
– –
INSM icon
53
Insmed
INSM
$27.5B
$7M 0.06%
400,000
– –
MGNX icon
54
MacroGenics
MGNX
$261M
$6.76M 0.06%
363,676
– –
ASMB icon
55
Assembly Biosciences
ASMB
$700M
$6.37M 0.05%
20,833
– –
CBAY
56
DELISTED
Cymabay Therapeutics
CBAY
$6.08M 0.05%
1,413,499
+1,104,231
+357% +$3.17M
LOXO
57
DELISTED
Loxo Oncology, Inc
LOXO
$5.8M 0.05%
137,735
– –
AKTX
58
Akari Therapeutics
AKTX
$15.3M
$5.5M 0.05%
621
– –
STML
59
DELISTED
Stemline Therapeutics, Inc.
STML
$5.42M 0.04%
633,497
+300,000
+90% +$2.73M
RXDX
60
DELISTED
Ignyta, Inc.
RXDX
$4.91M 0.04%
571,000
– –
ALDR
61
DELISTED
Alder Biopharmaceuticals
ALDR
$4.52M 0.04%
217,328
– –
BIIB icon
62
Biogen
BIIB
$32B
$4.51M 0.04%
16,500
– –
NBRV
63
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.2M 0.03%
1,400
– –
ANAB icon
64
AnaptysBio
ANAB
$1.71B
$4.16M 0.03%
+150,000
New +$3.49M
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
$4.14M 0.03%
381,939
-456,870
-54% -$4.63M
EPZM
66
DELISTED
Epizyme, Inc
EPZM
$3.99M 0.03%
232,481
– –
RARX
67
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.79M 0.03%
177,952
– –
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$2.55B
$3.39M 0.03%
50,000
– –
SYRS
69
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.26M 0.03%
20,447
– –
TRVN
70
DELISTED
Trevena, Inc.
TRVN
$3.15M 0.03%
1,372
+652
+91% +$2.22M
VIRX
71
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.04M 0.02%
21,190
– –
ADMS
72
DELISTED
Adamas Pharmaceuticals
ADMS
$3.02M 0.02%
172,630
– –
GNMX
73
DELISTED
Aevi Genomic Medicine Inc
GNMX
$3.01M 0.02%
1,618,089
+737,550
+84% +$3.34M
KPTI icon
74
Karyopharm Therapeutics
KPTI
$44.5M
$2.79M 0.02%
14,466
– –
TRIL
75
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.54M 0.02%
413,697
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2017 Portfolio in Review

As of Q1 2017, Julian Baker held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 88% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Julian Baker's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Julian Baker added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Julian Baker's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Julian Baker fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Julian Baker's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Julian Baker opened 4 new positions and closed 18 in Q1 2017.
  • Julian Baker's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.